376 related articles for article (PubMed ID: 34788507)
1. Multiyear Factor VIII Expression after AAV Gene Transfer for Hemophilia A.
George LA; Monahan PE; Eyster ME; Sullivan SK; Ragni MV; Croteau SE; Rasko JEJ; Recht M; Samelson-Jones BJ; MacDougall A; Jaworski K; Noble R; Curran M; Kuranda K; Mingozzi F; Chang T; Reape KZ; Anguela XM; High KA
N Engl J Med; 2021 Nov; 385(21):1961-1973. PubMed ID: 34788507
[TBL] [Abstract][Full Text] [Related]
2. Multiyear Follow-up of AAV5-hFVIII-SQ Gene Therapy for Hemophilia A.
Pasi KJ; Rangarajan S; Mitchell N; Lester W; Symington E; Madan B; Laffan M; Russell CB; Li M; Pierce GF; Wong WY
N Engl J Med; 2020 Jan; 382(1):29-40. PubMed ID: 31893514
[TBL] [Abstract][Full Text] [Related]
3. AAV5-Factor VIII Gene Transfer in Severe Hemophilia A.
Rangarajan S; Walsh L; Lester W; Perry D; Madan B; Laffan M; Yu H; Vettermann C; Pierce GF; Wong WY; Pasi KJ
N Engl J Med; 2017 Dec; 377(26):2519-2530. PubMed ID: 29224506
[TBL] [Abstract][Full Text] [Related]
4. Valoctocogene Roxaparvovec Gene Therapy for Hemophilia A.
Ozelo MC; Mahlangu J; Pasi KJ; Giermasz A; Leavitt AD; Laffan M; Symington E; Quon DV; Wang JD; Peerlinck K; Pipe SW; Madan B; Key NS; Pierce GF; O'Mahony B; Kaczmarek R; Henshaw J; Lawal A; Jayaram K; Huang M; Yang X; Wong WY; Kim B;
N Engl J Med; 2022 Mar; 386(11):1013-1025. PubMed ID: 35294811
[TBL] [Abstract][Full Text] [Related]
5. Hemophilia B Gene Therapy with a High-Specific-Activity Factor IX Variant.
George LA; Sullivan SK; Giermasz A; Rasko JEJ; Samelson-Jones BJ; Ducore J; Cuker A; Sullivan LM; Majumdar S; Teitel J; McGuinn CE; Ragni MV; Luk AY; Hui D; Wright JF; Chen Y; Liu Y; Wachtel K; Winters A; Tiefenbacher S; Arruda VR; van der Loo JCM; Zelenaia O; Takefman D; Carr ME; Couto LB; Anguela XM; High KA
N Engl J Med; 2017 Dec; 377(23):2215-2227. PubMed ID: 29211678
[TBL] [Abstract][Full Text] [Related]
6. Phase 1-2 Trial of AAVS3 Gene Therapy in Patients with Hemophilia B.
Chowdary P; Shapiro S; Makris M; Evans G; Boyce S; Talks K; Dolan G; Reiss U; Phillips M; Riddell A; Peralta MR; Quaye M; Patch DW; Tuddenham E; Dane A; Watissée M; Long A; Nathwani A
N Engl J Med; 2022 Jul; 387(3):237-247. PubMed ID: 35857660
[TBL] [Abstract][Full Text] [Related]
7. Two-Year Outcomes of Valoctocogene Roxaparvovec Therapy for Hemophilia A.
Mahlangu J; Kaczmarek R; von Drygalski A; Shapiro S; Chou SC; Ozelo MC; Kenet G; Peyvandi F; Wang M; Madan B; Key NS; Laffan M; Dunn AL; Mason J; Quon DV; Symington E; Leavitt AD; Oldenburg J; Chambost H; Reding MT; Jayaram K; Yu H; Mahajan R; Chavele KM; Reddy DB; Henshaw J; Robinson TM; Wong WY; Pipe SW;
N Engl J Med; 2023 Feb; 388(8):694-705. PubMed ID: 36812433
[TBL] [Abstract][Full Text] [Related]
8. Long-term follow-up of liver-directed, adeno-associated vector-mediated gene therapy in the canine model of hemophilia A.
Batty P; Mo AM; Hurlbut D; Ishida J; Yates B; Brown C; Harpell L; Hough C; Pender A; Rimmer EK; Sardo Infirri S; Winterborn A; Fong S; Lillicrap D
Blood; 2022 Dec; 140(25):2672-2683. PubMed ID: 35405003
[TBL] [Abstract][Full Text] [Related]
9. Emicizumab Prophylaxis in Patients Who Have Hemophilia A without Inhibitors.
Mahlangu J; Oldenburg J; Paz-Priel I; Negrier C; Niggli M; Mancuso ME; Schmitt C; Jiménez-Yuste V; Kempton C; Dhalluin C; Callaghan MU; Bujan W; Shima M; Adamkewicz JI; Asikanius E; Levy GG; Kruse-Jarres R
N Engl J Med; 2018 Aug; 379(9):811-822. PubMed ID: 30157389
[TBL] [Abstract][Full Text] [Related]
10. Long-Term Follow-Up of the First in Human Intravascular Delivery of AAV for Gene Transfer: AAV2-hFIX16 for Severe Hemophilia B.
George LA; Ragni MV; Rasko JEJ; Raffini LJ; Samelson-Jones BJ; Ozelo M; Hazbon M; Runowski AR; Wellman JA; Wachtel K; Chen Y; Anguela XM; Kuranda K; Mingozzi F; High KA
Mol Ther; 2020 Sep; 28(9):2073-2082. PubMed ID: 32559433
[TBL] [Abstract][Full Text] [Related]
11. AAV-mediated gene transfer for hemophilia.
High KA
Ann N Y Acad Sci; 2001 Dec; 953():64-74. PubMed ID: 11795424
[TBL] [Abstract][Full Text] [Related]
12. Characterization of Adeno-Associated Viral Vector-Mediated Human Factor VIII Gene Therapy in Hemophilia A Mice.
Greig JA; Wang Q; Reicherter AL; Chen SJ; Hanlon AL; Tipper CH; Clark KR; Wadsworth S; Wang L; Wilson JM
Hum Gene Ther; 2017 May; 28(5):392-402. PubMed ID: 28056565
[TBL] [Abstract][Full Text] [Related]
13. Long-term efficacy of adeno-associated virus serotypes 8 and 9 in hemophilia a dogs and mice.
Sarkar R; Mucci M; Addya S; Tetreault R; Bellinger DA; Nichols TC; Kazazian HH
Hum Gene Ther; 2006 Apr; 17(4):427-39. PubMed ID: 16610930
[TBL] [Abstract][Full Text] [Related]
14. Long-term safety and efficacy of factor IX gene therapy in hemophilia B.
Nathwani AC; Reiss UM; Tuddenham EG; Rosales C; Chowdary P; McIntosh J; Della Peruta M; Lheriteau E; Patel N; Raj D; Riddell A; Pie J; Rangarajan S; Bevan D; Recht M; Shen YM; Halka KG; Basner-Tschakarjan E; Mingozzi F; High KA; Allay J; Kay MA; Ng CY; Zhou J; Cancio M; Morton CL; Gray JT; Srivastava D; Nienhuis AW; Davidoff AM
N Engl J Med; 2014 Nov; 371(21):1994-2004. PubMed ID: 25409372
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of long-term prophylaxis in severe hemophilia A dogs following liver gene therapy using AAV vectors.
Sabatino DE; Lange AM; Altynova ES; Sarkar R; Zhou S; Merricks EP; Franck HG; Nichols TC; Arruda VR; Kazazian HH
Mol Ther; 2011 Mar; 19(3):442-9. PubMed ID: 21081906
[TBL] [Abstract][Full Text] [Related]
16. Advances in gene therapy for hemophilia: basis, current status, and future perspectives.
Ohmori T
Int J Hematol; 2020 Jan; 111(1):31-41. PubMed ID: 30083852
[TBL] [Abstract][Full Text] [Related]
17. BIVV001 Fusion Protein as Factor VIII Replacement Therapy for Hemophilia A.
Konkle BA; Shapiro AD; Quon DV; Staber JM; Kulkarni R; Ragni MV; Chhabra ES; Poloskey S; Rice K; Katragadda S; Fruebis J; Benson CC
N Engl J Med; 2020 Sep; 383(11):1018-1027. PubMed ID: 32905674
[TBL] [Abstract][Full Text] [Related]
18. Determining the Minimally Effective Dose of a Clinical Candidate Adeno-Associated Virus Vector in a Mouse Model of Hemophilia A.
Greig JA; Smith MK; Nordin JML; Goode T; Chroscinski EA; Buza EL; Schmidt N; Kattenhorn LM; Wadsworth S; Wilson JM
Hum Gene Ther; 2022 Apr; 33(7-8):421-431. PubMed ID: 34652966
[TBL] [Abstract][Full Text] [Related]
19. Early Phase Clinical Immunogenicity of Valoctocogene Roxaparvovec, an AAV5-Mediated Gene Therapy for Hemophilia A.
Long BR; Veron P; Kuranda K; Hardet R; Mitchell N; Hayes GM; Wong WY; Lau K; Li M; Hock MB; Zoog SJ; Vettermann C; Mingozzi F; Schweighardt B
Mol Ther; 2021 Feb; 29(2):597-610. PubMed ID: 33309883
[TBL] [Abstract][Full Text] [Related]
20. A single adeno-associated virus (AAV)-murine factor VIII vector partially corrects the hemophilia A phenotype.
Sarkar R; Xiao W; Kazazian HH
J Thromb Haemost; 2003 Feb; 1(2):220-6. PubMed ID: 12871492
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
